Healthcare AI Company Market Map
Clinical Decision Support and Predictive Risk
Models that predict deterioration, sepsis onset, or readmission risk and surface it to clinicians as an alert or recommendation.
Buyer Brief
- Best-fit buyer
- CMIO, quality and safety, nursing leadership, clinical informatics, data science, and service-line owners
- Primary use case
- Surface patient risk, deterioration signals, or clinical recommendations for review
- Typical deployment
- Usually embedded in the EHR or connected to streaming clinical data with alerts delivered inside existing workflows
A strong retrospective model can still fail in live care. Buyers need prospective evidence, local validation, clear ownership, and an off switch tied to monitored thresholds.
Companies in This Category
| Company | What it does | Stock or ownership | Research next |
|---|---|---|---|
| Epic | Not a standalone AI vendor, but the place most predictive models actually run. Epic ships native predictive models and an increasing amount of generative capability inside the record, which means the EHR is often the real competitor to any point solution in this group. | No direct public shares are available. | Company research Official site |
| Bayesian Health | Real-time clinical deterioration and sepsis detection built around reducing alert fatigue, with published work on prospective validation rather than retrospective accuracy alone. | No direct public shares are available. | Company research Official site |
| Navina | AI assistant that brings patient history into chart review and value-based care. It supports diagnosis documentation and care-gap work using information from existing records. | No current public listing was verified. | Company research Official site |
| Regard | AI clinical support that reviews patient records for possible missed diagnoses and drafts documentation for clinician review. Its products also support hospital revenue work and risk adjustment. | No current public listing was verified. | Company research Official site |
| Anumana | ECG-AI reads a standard 12-lead ECG and flags signs of heart disease for a clinician to review. Anumana holds FDA clearances covering low ejection fraction, pulmonary hypertension and cardiac amyloidosis, so a hospital can look for those conditions in a test it already runs every day. | No current public listing was verified. | Company research Official site |
What to Verify Before Shortlisting
Evidence
- What population, prevalence, and care setting were used for validation?
- Has the tool been tested prospectively against the current workflow?
- What clinical and operational outcomes improved beyond model accuracy?
Regulatory and workflow
- Does the intended use place the software under FDA device oversight?
- What does the clinician see before acting on the score or alert?
- Who owns performance review, adverse event review, and suspension decisions?
Data and contracts
- Which inputs are required and how are missing or delayed data handled?
- How are model updates, feature changes, and drift disclosed?
- Can local performance be measured by patient subgroup and clinical unit?
The question that matters: What population the model was validated on. A sepsis model trained on one health system can behave very differently on a different demographic and case mix.
Directory inclusion is editorial and does not imply endorsement. Product capabilities, contracts, and regulatory status can change. Verify claims with the company and the relevant regulator before procurement.